Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120075 · ClinicalTrials.gov registry record · Phase 1
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
A Phase 1 study of Advanced Cancer, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 10
- Study locations
NCT06120075 is a Phase 1 study of Advanced Cancer that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 91 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (63% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT06120075, a Phase 1 study of Advanced Cancer, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG AB801
Study Locations (10)
Texas
- Mary Crowley - Dallas
- START - South Texas Accelerated Research Therapeutics, LLC. - San Antonio
Colorado
- Sarah Cannon Research Institute - Denver
District of Columbia
- Georgetown - Washington D.C.
Georgia
- Emory University - Atlanta
Michigan
- START Midwest - Grand Rapids
New York
- Icahn School of Medicine at Mount Sinai/ The Tisch Cancer Center - New York
Pennsylvania
- University Of Pennsylvania, Abramson Cancer Center - Philadelphia
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120075
The ClinicalTrials.gov registry entry for NCT06120075 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT06120075 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06120075 about?
NCT06120075 is a clinical study titled "A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies". The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
What is the current status of trial NCT06120075?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2024-01-19. Estimated completion is 2026-11.
What conditions does trial NCT06120075 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT06120075?
The interventions under investigation include: Docetaxel (DRUG), AB801 (DRUG).
Who is sponsoring clinical trial NCT06120075?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120075 being conducted?
This trial has 10 study locations across Colorado, District of Columbia, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.